Nonalcoholic Steatohepatitis Treatment Market USD 19.8 Billion by 2025, Research Study by iHealthcareAnalyst, Inc.
The global nonalcoholic steatohepatitis treatment market is estimated to reach USD 19.5 Billion in 2025, expanding at a CAGR of 10.0% from 2016 to 2025.
Maryland Heights, MO, October 30, 2016 --(PR.com)-- According to a market research report Nonalcoholic Steatohepatitis Treatment Market 2015-2025 published by iHealthcareAnalyst, Inc., the global nonalcoholic steatohepatitis treatment market is estimated to reach USD 19.5 Billion in 2025, expanding at a CAGR of 10.0% from 2016 to 2025.
Visit the Nonalcoholic Steatohepatitis Treatment Market 2015-2025 report at https://www.ihealthcareanalyst.com/report/nonalcoholic-steatohepatitis-treatment-market/.
Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a buildup of fat in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease. Non-alcoholic fatty liver disease (NAFLD) is one of the causes of fatty liver, occurring when fat is deposited (steatosis) in the liver due to causes other than excessive alcohol use.
The global nonalcoholic steatohepatitis treatment market report provides market size (Revenue USD Million 2013 to 2020), market share, market trends and forecasts growth trends (CAGR%, 2016 to 2020).
The global nonalcoholic steatohepatitis treatment market segmentation is based on phase III drugs in pipeline (Obeticholic Acid, Aramchol, Saroglitazar, and Elafibranor). The global nonalcoholic steatohepatitis treatment market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
1. Drug Type
1.1 Phase III Drugs
1.1.1 Aramchol (Arachidyl Amido Cholanoic Acid)
1.1.2 Elafibranor
1.1.3 Obeticholic Acid (OCA)
1.1.4 Saroglitazar
1.2 Phase I and II Drugs
2. Geography (Region, Country)
2.1 North America (U.S., Canada)
2.2 Latin America (Brazil, Mexico, Rest of LA)
2.3 Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4 Asia Pacific (Japan, China, India, Rest of APAC)
2.5 Rest of the World
3. Company Profiles
3.1 AstraZeneca plc
3.2 Conatus Pharmaceuticals
3.3 Galmed Pharmaceuticals
3.4 Genfit Sa
3.5 Gilead Sciences Inc.
3.6 Immuron Ltd.
3.7 Intercept Pharmaceuticals Inc.
3.8 Tobira Therapeutics Inc.
3.9 Zydus Cadila
About Us
iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.
Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareranalyst.com
Website: https://www.ihealthcareanalyst.com
Visit the Nonalcoholic Steatohepatitis Treatment Market 2015-2025 report at https://www.ihealthcareanalyst.com/report/nonalcoholic-steatohepatitis-treatment-market/.
Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a buildup of fat in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease. Non-alcoholic fatty liver disease (NAFLD) is one of the causes of fatty liver, occurring when fat is deposited (steatosis) in the liver due to causes other than excessive alcohol use.
The global nonalcoholic steatohepatitis treatment market report provides market size (Revenue USD Million 2013 to 2020), market share, market trends and forecasts growth trends (CAGR%, 2016 to 2020).
The global nonalcoholic steatohepatitis treatment market segmentation is based on phase III drugs in pipeline (Obeticholic Acid, Aramchol, Saroglitazar, and Elafibranor). The global nonalcoholic steatohepatitis treatment market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
1. Drug Type
1.1 Phase III Drugs
1.1.1 Aramchol (Arachidyl Amido Cholanoic Acid)
1.1.2 Elafibranor
1.1.3 Obeticholic Acid (OCA)
1.1.4 Saroglitazar
1.2 Phase I and II Drugs
2. Geography (Region, Country)
2.1 North America (U.S., Canada)
2.2 Latin America (Brazil, Mexico, Rest of LA)
2.3 Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4 Asia Pacific (Japan, China, India, Rest of APAC)
2.5 Rest of the World
3. Company Profiles
3.1 AstraZeneca plc
3.2 Conatus Pharmaceuticals
3.3 Galmed Pharmaceuticals
3.4 Genfit Sa
3.5 Gilead Sciences Inc.
3.6 Immuron Ltd.
3.7 Intercept Pharmaceuticals Inc.
3.8 Tobira Therapeutics Inc.
3.9 Zydus Cadila
About Us
iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.
Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareranalyst.com
Website: https://www.ihealthcareanalyst.com
Contact
iHealthcareAnalyst, Inc.
Ana Aitawa
(314) 736-9294
http://www.ihealthcareanalyst.com/
Ana Aitawa
(314) 736-9294
http://www.ihealthcareanalyst.com/
Contact
Categories